RF Acquisition Corp II (RFAI) is a Singapore-headquartered blank-check company, incorporated in the Cayman Islands and listed on Nasdaq in 2024. It has no operating business of its own; its purpose is to merge with a private company, and it has been pursuing an agreement with Singapore-based AI drug discovery firm Nanyang Biologics Pte. Ltd., a transaction described at roughly $1.5 billion in value that would create a listed entity called NYB Holdings Limited.
In the current session the shares changed hands at $34.10, up $1.90 or 5.90%, from the previous completed close of $32.20. The direction is unambiguously higher. No verified news release, SEC filing, or analyst action was found to explain the advance, leaving market microstructure — thin float, wide spreads, and momentum from the prior session — as the most plausible driver.
No verified news or fundamental catalyst found ahead of the session explains the size of the move. A scan of corporate announcements, regulatory filings, wire coverage, and analyst commentary produced nothing published before or during the session that would materially change the value of the company or its pending transaction.
The background is well known to holders: shareholders overwhelmingly approved the Nanyang Biologics combination at an extraordinary general meeting in August 2026, with more than 6.7 million votes cast in favor, alongside an equity incentive plan and governance changes required for Nasdaq listing. Nothing new on that front surfaced today.
The most defensible assessment is that this is a thin-float, momentum-driven move. Roughly 3.96 million shares were submitted for redemption around the merger vote, leaving a small tradable float, and the stock has repeatedly posted double-digit sessions on modest turnover. It has become standard for this name to move several percent on virtually no headline, a pattern consistent with speculative trading in a low-liquidity, event-driven SPAC. The rebound also follows a pullback from $34.67 on November 13 to $28.00 on November 17, a decline of nearly 19%, so part of today's gain looks like a recovery from that slide rather than a fresh re-rating.
Turnover remained light relative to the broader market and roughly in line with the stock's modest average. With average daily volume near 75,000 shares and a market value of about $140 million, RFAI trades in a liquidity environment where a single moderate order can move the quote by several percent — the key mechanical reason a 5.90% gain can occur without news.
The move appears idiosyncratic rather than sector-driven. No verified development in AI-enabled drug discovery, blank-check issuance, or Asian technology listings coincided with the session, and there is no read-through from a peer that would justify a re-rating of this specific shell. The shares are not tracking broad benchmarks on a percentage basis in any meaningful way given their size and float.
On the technical side, the stock has pushed back above its 20-day average, which sits near $31.40, after briefly breaking below $28 earlier in the week. It remains well under the $40 to $52 range where it traded through much of the third quarter and roughly half of its August 21 intraday peak of $73.00. Volatility pauses have been a recurring feature of this name, a further sign of an order book that thins quickly around news and rumor.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. RFAI earns 8 out of 100.
Verified news strength was negligible: no filing, announcement, or analyst action accompanied the session, and the merger approval that drives the investment case is months old. The price move was equally unremarkable by this stock's standards — 5.90% is slightly below its average absolute daily move of roughly 6.5%, and 24 of the past 62 sessions produced moves of equal or greater size, on volume that was not elevated. Weak news and a routine swing combine to a low score.
The central variable remains completion of the Nanyang Biologics business combination and the subsequent Nasdaq listing of the combined company. Final redemption numbers will determine how much trust cash survives to fund the business and how small the post-closing float becomes — a factor that cuts both ways for volatility.
Because RFAI is a shell, it reports no operating revenue and no traditional earnings guidance; quarterly results consist largely of trust interest income and transaction costs, so near-term attention centers on filings rather than income statements. The company has relied on monthly trust deposits funded by the target to keep its combination window open, and any interruption in that funding would be material.
Key risks include failure to satisfy remaining closing conditions, which would push the company toward liquidation at roughly trust value; heavy dilution from sponsor and target share issuances; the expiry of lock-up restrictions after closing; and the persistent risk that a low-float, headline-sensitive security swings violently on little fundamental information. Nanyang's clinical and preclinical pipeline progress, including its lead oncology candidate, will matter far more once the merger is complete than it does today.
Tickeron's Trending AI Robots page is a curated view of the platform's best-performing automated strategies under present market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and each bot differs by strategy logic, holding period, performance metrics, and the symbols it trades. Rather than listing the full catalog, the Trending section surfaces only those robots currently showing the strongest results, making it easier for users to compare approaches at a glance. It is a practical starting point for anyone evaluating systematic trading tools.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RFAI advanced for three days, in 12 of 52 cases, the price rose further within the following month. The odds of a continued upward trend are 23%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 4 of 25 cases where RFAI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 16%.
The Moving Average Convergence Divergence (MACD) for RFAI just turned positive on November 18, 2026. Looking at past instances where RFAI's MACD turned positive, the stock continued to rise in 6 of 34 cases over the following month. The odds of a continued upward trend are 18%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RFAI as a result. In 5 of 40 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 12%.
RFAI moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RFAI crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 1 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RFAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
RFAI broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. RFAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.558) is normal, around the industry mean (-543.067). P/E Ratio (267.667) is within average values for comparable stocks, (119.427). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (18.598). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. RFAI's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RFAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry FinancialConglomerates